NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates ...0

News by : (PR Newswire) -

Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization Phase 3 study design for PrimeC in ALS aligned...

Read More Details
Finally We wish PressBee provided you with enough information of ( NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates )

Also on site :

Most Viewed News
جديد الاخبار